The Amyloidosis Channel is supported through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | A new era for BCMA-targeted bispecific antibodies in AL amyloidosis?
Giada Bianchi, MD, Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA, discusses the potential of BCMA-targeted bispecific antibodies in light chain (AL) amyloidosis, including elranatamab, which is being evaluated in a Phase I/II study (NCT06569147) in patients with at least one prior line of therapy. Dr Bianchi highlights the rapid and deep responses observed with BCMA-directed bispecific antibodies and discusses their potential role in earlier lines of treatment. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, yeah, this is a question close to my heart, actually. So we currently have an open-label Phase I/II study evaluating the BCMA-targeting bispecific elranatamab in patients who have previously received at least one line of therapy with light-chain amyloidosis. So agents such as elranatamab, teclistamab, etentamig, linvoseltamab, I’m sorry, there are so long names, they’re entering the field of amyloidosis and they’re entering the field of amyloidosis with really quite a staggering signal of efficacy...
Yeah, yeah, this is a question close to my heart, actually. So we currently have an open-label Phase I/II study evaluating the BCMA-targeting bispecific elranatamab in patients who have previously received at least one line of therapy with light-chain amyloidosis. So agents such as elranatamab, teclistamab, etentamig, linvoseltamab, I’m sorry, there are so long names, they’re entering the field of amyloidosis and they’re entering the field of amyloidosis with really quite a staggering signal of efficacy. So across agents we see pretty much universal responses. These responses are so rapid we have never witnessed before in a matter of weeks time as compared to months time. And the responses are profound. The light chain basically become undetectable and unmeasurable in the blood. So it is really where we are headed in light chain amyloidosis. The major question that was out there is can this often frail patient population tolerate these therapies that do have risk for cytokine release syndrome, and other toxicity. And so far, it seems that the toxicity profile across the board, both in the short and long-term vision, appears very safe and sort of tolerable in the setting of what it is an underlying illness that is quite severe. So this is a very exciting era I think for patients with light chain amyloidosis and certainly BCMA bispecific will have a role in treating these patients and are likely to move in the front line very soon.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
